肾细胞癌精准靶向治疗的研究进展

Abstract
Figure/Table
References (39)
Related Citation (15)

Download: PDF (0 KB) HTML (54 KB)
Export: BibTeX | EndNote (RIS)

Abstract Renal cell carcinoma（RCC）originates from urinary tubules′epithelial system of ren al parenchyma.It often occurs in one side of kidney.It is one of themost common malignant tumors in urinary system.Angiogenesis，the lack of VHL gene or mutation，two major signal pathways excessively activated of Raf/MEK/ERK and PI3K/AKT/mTOR lead the happenning and development of RCC.However RCC isn′t sensitive to conventional radiotherapy and chemotherapy，hormone therapy and biological treatment along with huge side effects.Therefore，accurate targeted therapy is often used for RCC now.Patients after relative genes and markers detection，are taken drug combination to target precisely for differences.It largely improves the efficiency of the treatment，and reduces the side effects.After a period of treatment of RCC，drug resistance always appears.Drug resistance is divided into acquired drug resistance and primary drug resistance，seriously affecting the therapeutic effect and prognosis of patients.Reviewing the pathogenesis of accurating targeted therapy and drug resistance of RCC is the aimsof this article.

Key words： Renal cell carcinoma Signal pathways Genemutation VHL gene Drug resistance Biomarker Accurate targeted therapy

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CHEN Xu
	ZHANGHong-xiu
	NIEMing-xiu
	LIWei

Cite this article:

CHEN Xu,ZHANGHong-xiu,NIEMing-xiu, et al. The accurate targeted therapeutic research progressof renal cell carcinoma[J]. 中国当代医药, 2016, 23(21): 14-17.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2016/V23/I21/14

［27］	Kasenda B，Larkin J，Gore M.Immunotherapies in early and advanced renal cell cancer［J］.Prog Tumor Res，2015，42（1）：1-10.
［29］	Sosman J，Puzanov I.Combination targeted therapy in advanced renal cell carcinoma［J］.Cancer，2009，115（10 Suppl）：2368-2375.
［1］	Thoenes W，Störkel S，Rumpelt HJ.Histopathology and classification of renal cell tumors（adenomas，oncocytomas and carcinomas）.The basic cytological and histopathological elementsand their use for diagnostics［J］.Pathol Res Pract，1986，181（2）：125-143.
［2］	Siegel R，Naishadham D，Jemal A.Cancer statistics，2013［J］. CA Cancer JClin，2013，63（1）：11-30.
［3］	Ferlay J，Soerjomataram I，Ervik M，et al.GLOBOCAN 2012 v1.0，cancer incidence and mortality worldwide：IARC cancer base No.11 Lyon，France：I nternational Agency for Research on Cancer［EB/OL］.http：//globo-can.iarc.fr
［4］	张永贞，杨国庆，张思维，等.中国2009年肾及泌尿系统其他癌发病和死亡分析［J］.中国肿瘤，2013，22（5）：34-36.
［5］	Lohse CM，Gupta S，Cheville JC.Outcome prediction for patientswith renal cell carcinoma［J］.Semin Diagn Pathol，2015，32（2）：172-183.
［6］	张洪秀，聂明秀，李伟.晚期肾癌靶向治疗现状［J］.现代泌尿生殖肿瘤杂志，2014，6（6）：375-377.
［7］	Ferlay J，Soerjomataram I，Dikshit R，et al.Cancer incidence and mortality worldwide∶sources，methods and major patterns in GLOBOCAN 2012［J］.Int JCancer，2015，136（5）：E359-E386.
［8］	Znaor A，Lortet-Tieulent J，Laversanne M，etal.International variations and trends in renal cell carcinoma incidence and mortality［J］.Eur Urol，2015，67（3）：519-530.
［9］	聂明秀，马普能，张洪秀，等.VEGF165b的抗血管生成作用在肾癌发生、发展中的研究进展［J］.中国当代医药，2015，22（9）：26-28.
［10］	Lièvr A.Les antiangiogéniques［J］.Retour Au Numéro，2007，144（3）：7-11.
［11］	Hanna SC，Heathcote SA，Kim WY.mTOR pathway in renal cell carcinoma［J］.Expert Rev Anticancer Ther，2008，8（2）：283-292.
［12］	Kaelin WG Jr.The von Hippel-Lindau tumour suppressor protein：O2sensing and cancer［J］.Nat Rev Cancer，2008，8（11）：865-873.
［15］	寿建忠，马建辉.肾癌的靶向治疗现状与进展［J］.中国新药杂志，2010，19（17）：1539-1546.
［22］	Chiara Battelli，Daniel C Cho.mTOR inhibitors in renal cell carcinoma［J］.Therapy，2011，8（4）：359-367.
［23］	Hudes GR.TargetingmTOR in renal cell carcinoma［J］.Cancer，2009，115（10 Suppl）：2313-2320.
［25］	Liu Y，An S，Ward R，et al.G protein-coupled receptors as promising cancer targets［J］.Cancer Lett，2016，376（2）：226-239.
［13］	Latif F，Tory K，Gnarra JR，et al.Identification of the von Hippel-Lindau disease tumor suppressor gene［J］.Science，1993，260（5112）：1317-1320.
［14］	Motzer RJ，Hutson TE，Tomczak P，et al.Sunitinib versus interferon alfa inmetastatic renal-cell carcinoma［J］.N Engl JMed，2007，356（2）：115-124.
［16］	Dancey J，Sausville EA.Issues and progress with protein kinase inhibitors for cancer treatment［J］.Nat Rev Drug Discov，2003，2（4）：296-313.
［17］	Kolch W，Kotwaliwale A，Vass K，et al.The role of Raf kinases in malignant transformation［J］.Expert Rev Mol Med，2002，4（8）：1-18.
［18］	Kolch W.Meaningful relationships：the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions［J］. Biochem J，2000，35（2）：289-305.
［19］	Savelyeva L，Schwab M.Amplification of oncogenes revisited：from expression profiling to clinical application［J］.Cancer Lett，2001，167（2）：115-123.
［20］	Gollob JA，Wilhelm S，Carter C，et al.Role of Raf kinase in cancer：therapeutic potential of targeting the Raf/MEK/ ERK signal transduction pathway［J］.Semin Oncol，2006，33（4）：392-406.
［21］	Polivka J Jr，Janku F.Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway［J］.Pharmacol Ther，2014，142（2）：164-175.
［24］	Yang JC，Haworth L，Sherry RM，et al.A randomized trial of bevacizumab，an anti-vascular endothelial growth factor antibody，for metastatic renal cancer［J］.N Engl J Med，2003，349（5）：427-434.
［26］	Buti S，Bersanelli M，Sikokis A，et al.Chemotherapy in metastatic renal cell carcinoma today？A systematic review［J］. Anticancer Drugs，2013，24（6）：535-554.
［28］	Parton M，Gore M，Eisen T.Role of cytokine therapy in 2006 and beyond formetastatic renal cell cancer［J］.JClin Oncol，2006，24（35）：5584-5592.
［30］	Sheppard KE，Cullinane C，Hannan KM，et al.Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors［J］. Eur JCancer，2013，49（18）：3936-3944.
［31］	Roberts PJ，Usary JE，Darr DB，et al.Combined PI3K/ mTOR and MEK inhibition providesbroad antitumoractivity in faithfulmurine cancermodels［J］.Clin Cancer Res，2012，18（19）：5290-5303.
［32］	Mclornan DP，List A，Mufti GJ.Applying synthetic lethality for the selective targeting of cancer［J］.New Engl JMed，2014，371（18）：1725-1735.
［33］	Pfister SX，Markkanen E，Jiang Y，et al.Inhibiting WEE1 selectively kills histone H3K36me3-deficient cancers by dNTP starvation［J］.Cancer Cell，2016，28（5）：557-568.
［34］	Penticuff JC，Kyprianou N.Therapeutic challenges in renal cell carcinoma［J］.Am JClin Exp Urol，2015，3（2）：77-90.
［35］	Rau KM，Chen HK，Shiu LY，et al.Discordance ofmutation statuses of epidermal growth factor receptor and K-Ras between primary adenocarcinoma of lung and brain metastasis［J］.Int JMol Sci，2016，17（4）：E524.
［36］	Qu L，Ding J，Chen C，et al.Exosome-transmitted IncARSR promotes sunitinib resistance in renal cancer by acting as a competing endogenous RNA［J］.Cancer cell，2016，29（5）：653-668.
［37］	Sakai I，Miyake H，Fujisawa M.Acquired resistance to sunitinib in human renal cell carcinoma cells ismediated by constitutive activation of signal transduction pathways associated with tumour cell proliferation［J］.BJU Int，2013，112（2）：E211-E220.
［38］	Tamaskar I，Dhillon J，Pili R.Resistance to angiogenesis inhibitorsin renal cell carcinoma［J］.Clin Adv HematolOncol，2011，9（2）：101-110.
［39］	Rowe SP，Gorin MA，Hammers HJ，et al.Detection of 18FFDG PET/CT occult lesions with 18F-DCFPyL PET/CT in a patientwith metastatic renal cell carcinoma［J］.Clin Nucl Med，2016，41（1）：83-85.